HC Wainwright & Co. analyst Yi Chen reiterates First Wave BioPharma (NASDAQ:FWBI) with a Buy.
Reported Late Monday, Precigen Announces Phase 1 Dose Escalation Data For Autologous PRGN-3006 UltraCAR-T Manufactured Overnight For Next Day Infusion In Relapsed Or Refractory Acute Myeloid Leukemia Patients
– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow –
– PRGN-3006 infusion
